Biotech: Page 3

  • The Wall Street sign in the Financial District of Lower Manhattan in New York City.
    Image attribution tooltip
    hapabapa via Getty Images
    Image attribution tooltip

    Biotech stock fundings headed for best quarter in 3 years, Jefferies says

    Publicly traded companies raised nearly $10 billion in follow-on stock offerings in January and February, a financing surge that’s driving a “sector recovery,” the investment bank said. 

    By • March 11, 2024
  • Young woman in a hospital being registered using a tablet computer
    Image attribution tooltip
    andresr via Getty Images
    Image attribution tooltip
    Sponsored by PurpleLab

    Can using SDoH data help identify patient populations who could benefit from weight loss drugs?

    SDoH data can help companies understand the footprint of weight loss medications in the market and their impact across populations.

    March 11, 2024
  • Colorized scanning electron micrograph of a natural killer cell from a human donor. Explore the Trendline➔
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Cell therapy

    Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches.

    By BioPharma Dive staff
  • The logo of Amylyx Pharmaceuticals is seen through an office window.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip

    Amylyx ALS drug fails crucial study, putting company’s future in doubt

    The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.

    By • Updated March 8, 2024
  • The Nasdaq Marketplace is seen on March 01, 2024 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Boundless Bio, a Bayer-backed cancer biotech, seeks an IPO

    The startup, which has raised nearly $254 million privately, is in early testing with drugs designed to target particularly tough-to-treat tumors.

    By • March 7, 2024
  • A stock market graph overlaid on a laptop and stack of coins.
    Image attribution tooltip
    Stadtratte via Getty Images
    Image attribution tooltip

    European VC Invivo readies its latest fund to back new biotechs

    The Barcelona-based firm, which is targeting about 100 million euros for the new fund, is eyeing investments in AI, synthetic biology, and cell and gene therapy.

    By • March 6, 2024
  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Maximusnd via Getty Images
    Image attribution tooltip

    Alumis, taking aim at Bristol Myers, pulls in $259M for TYK2 drug work

    The startup, one of a number of young biotechs coming after Bristol Myers’ Sotyktu, will use the cash to fund a late-stage trial in plaque psoriasis.

    By • March 6, 2024
  • A person works in Sionna Therapeutics' lab.
    Image attribution tooltip
    Permission granted by Sionna Therapeutics
    Image attribution tooltip
    Emerging biotech

    Sionna raises another $182M to challenge Vertex in cystic fibrosis

    Incubated by RA Capital and backed by a wide array of investors, the startup is developing drugs that work differently than Vertex’s market-leading medicines.

    By • March 6, 2024
  • The staff of CG Oncology rings the opening bell at Nasdaq as confetti falls.
    Image attribution tooltip
    Permission granted by Nasdaq, Inc.
    Image attribution tooltip
    Emerging biotech

    Biotech IPOs heated up to start 2024. Will the surge last?

    Following the sector’s best IPO start in three years, BioPharma Dive spoke with industry insiders about what they expect to see in the months ahead. 

    By , • March 5, 2024
  • A woman coughs into her hand while sitting under a blanket.
    Image attribution tooltip
    Prostock-Studio via Getty Images
    Image attribution tooltip

    Nocion, chasing GSK, pulls in $62M for chronic cough drug

    Nocion will use the cash to start a mid-stage trial testing its medicine, a potential rival to a drug GSK acquired last year in a $2 billion deal.

    By • March 4, 2024
  • human heart
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Bayer pays $310M to buy into BridgeBio heart drug

    The deal gives the German pharma partial rights to a closely watched medicine for transthyretin amyloidosis cardiomyopathy that analysts expect to become a multibillion-dollar product.

    By • March 4, 2024
  • Illustration of doctor and patient discussing scientific biomedical shapes.
    Image attribution tooltip
    Permission granted by QIAGEN
    Image attribution tooltip
    Sponsored by QIAGEN

    Using knowledge graphs to drive drug discovery

    How are knowledge graphs changing the path of drug discovery?

    March 4, 2024
  • A man dressed in a suit looks at the camera in this headshot.
    Image attribution tooltip
    Permission granted by FogPharma
    Image attribution tooltip

    FogPharma pulls in $145M to support cancer drug research

    The cash will be used to advance development of FOG-001, the company’s lead drug that’s now being tested in an early-stage trial for solid tumors.

    By • March 1, 2024
  • A stock photo of blocks arranged to illustrate layoffs
    Image attribution tooltip
    Andrii Yalanskyi via Getty Images
    Image attribution tooltip

    Gritstone to lay off 40% of workforce after costly study delay

    The restructuring comes ahead of a key study readout for Gritstone, which, like Moderna, is developing a type of personalized cancer vaccine.

    By • March 1, 2024
  • Three business men stand on a city street for a photo
    Image attribution tooltip
    Courtesy of Cure Ventures
    Image attribution tooltip

    Cure Ventures backs a cell therapy startup targeting Parkinson’s

    The startup, Kenai Therapeutics, has raised $82 million and will be chaired by Jeff Jonas, a new Cure partner and former CEO of Sage Therapeutics.

    By • Feb. 29, 2024
  • Several California poppies are seen in bloom.
    Image attribution tooltip
    GomezDavid via Getty Images
    Image attribution tooltip

    With BlossomHill, former Turning Point execs take aim at cancer, autoimmune disease

    Less than two years after Bristol Myers bought Turning Point for $4.1 billion, Jean Cui and Peter Li have built a new startup that’s brought in more than $170 million in funding. 

    By • Feb. 29, 2024
  • A logo of Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip

    Abingworth invests in Trodelvy development in deal with Gilead

    One of the investment firm’s startups will work with Gilead to expand the cancer drug’s label under the unusual arrangement, with Abingworth receiving payment if successful.

    By Kristin Jensen • Feb. 29, 2024
  • A blurred photo of an empty laboratory
    Image attribution tooltip
    Ozankutsal via Getty Images
    Image attribution tooltip

    Women’s health company Obseva to wind down, lay off staff

    The company is still attempting to “monetize” its most advanced drug, a treatment to aid pregnancy via in vitro fertilization.

    By • Feb. 28, 2024
  • Image attribution tooltip
    Idorsia Ltd.
    Image attribution tooltip

    Viatris pays $350M to gain two drugs from Idorsia

    The deal gives Viatris access to a treatment for heart attacks as well as a drug for lupus, both of which are currently in Phase 3 testing.

    By Kristin Jensen • Feb. 28, 2024
  • A photo of a Gingko Bioworks office
    Image attribution tooltip
    Courtesy of Ginkgo Bioworks
    Image attribution tooltip

    Ginkgo adds gene editing tools in buyout of Feng Zhang-founded startup

    The acquisition of Proof Diagnostics, which was formed to develop a COVID-19 test, gives Ginkgo a library of novel enzymes for making genetic medicines.

    By • Feb. 28, 2024
  • A man in a blue shirt looks into the camera for a headshot photograph.
    Image attribution tooltip
    Permission granted by Lindus Health
    Image attribution tooltip

    Can a Moderna co-founder change the CRO game?

    Well-known scientist and biotech entrepreneur Robert Langer is helping Lindus Health address longstanding challenges in contract drug research.

    By Michael Gibney • Feb. 28, 2024
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip

    Viking data suggest obesity drug could rival Zepbound, Wegovy

    The biotech’s drug led to significant weight loss in a Phase 2 trial, causing shares to double as analysts compared results to the marks set by drugs from Eli Lilly and Novo Nordisk.

    By • Feb. 27, 2024
  • A concept illustration of malignant cells, colored purple and red
    Image attribution tooltip
    koto_feja via Getty Images
    Image attribution tooltip

    Janux shares triple on early cancer immunotherapy data

    Analysts viewed results for one of Janux’s drug, a T cell engager aimed at metastatic prostate cancer, as potentially best-in-class in a field that’s crowded with competitors.

    By • Feb. 27, 2024
  • A candlestick stock chart is seen out of focus against a background of $100 dollar bills in this composite stock image.
    Image attribution tooltip
    Honglouwawa via Getty Images
    Image attribution tooltip

    Denali, fresh off study setback, gets $500M lift

    The infusion from unnamed private investors will bolster the company’s balance sheet days after a Sanofi-partnered ALS drug stumbled in a clinical trial.

    By • Feb. 27, 2024
  • An illustration of red blood cells
    Image attribution tooltip
    ismagilov via Getty Images
    Image attribution tooltip

    BioMarin preaches patience amid slow sales for hemophilia gene therapy

    The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.

    By • Feb. 23, 2024
  • A headshot of Chris Varma, CEO of Frontier Medicines.
    Image attribution tooltip
    Permission granted by Frontier Medicines
    Image attribution tooltip

    Frontier gets $80M, Galapagos’ backing to make a better KRAS drug

    The startup’s Series C round will support a clinical-stage drug the company thinks could address the shortcomings of other KRAS-targeting medicines.

    By • Feb. 22, 2024